Source: NICE
Area: News
NICE has published a costing statement to accompany its guidance on fluocinolone acetonide intravitreal implant (Iluvien) for the treatment of chronic diabetic macular oedema (DMO) considered insufficiently responsive to available therapies (TA 271).
Because fluocinolone acetonide is not recommended for routine use within the NHS, NICE do not anticipate a significant impact on NHS resources.
See links below for further details.
Uncategorized